CR11372A - Inhibidores de beta-lactamasa - Google Patents

Inhibidores de beta-lactamasa

Info

Publication number
CR11372A
CR11372A CR11372A CR11372A CR11372A CR 11372 A CR11372 A CR 11372A CR 11372 A CR11372 A CR 11372A CR 11372 A CR11372 A CR 11372A CR 11372 A CR11372 A CR 11372A
Authority
CR
Costa Rica
Prior art keywords
beta
inhibitors
lactamasa
alpha
amino
Prior art date
Application number
CR11372A
Other languages
English (en)
Inventor
J Burns Christopher
W Jackson Randy
Goswami Rajesh
Hongyu
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of CR11372A publication Critical patent/CR11372A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En la presente se dan a conocer acidos alfa-amino-boronicos y sus derivados, los cuales actuan como inhibidores de beta-lactamasas. Tambien, en la presente se dan a conocer composiciones farmaceuticas que comprenden acidos alfa-amino-boronicos, y metodos de uso de las mismas
CR11372A 2007-11-13 2010-04-15 Inhibidores de beta-lactamasa CR11372A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US279707P 2007-11-13 2007-11-13

Publications (1)

Publication Number Publication Date
CR11372A true CR11372A (es) 2010-09-14

Family

ID=40344560

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11372A CR11372A (es) 2007-11-13 2010-04-15 Inhibidores de beta-lactamasa

Country Status (21)

Country Link
US (2) US20100286092A1 (es)
EP (2) EP2220097A1 (es)
JP (2) JP2011504468A (es)
KR (2) KR20100113485A (es)
CN (2) CN101861324A (es)
AR (2) AR069463A1 (es)
AU (2) AU2008321444A1 (es)
BR (2) BRPI0820531A2 (es)
CA (2) CA2705393A1 (es)
CO (1) CO6331427A2 (es)
CR (1) CR11372A (es)
EA (2) EA201000774A1 (es)
EC (1) ECSP10010246A (es)
GT (1) GT201000143A (es)
IL (1) IL205205A0 (es)
MA (1) MA31874B1 (es)
MX (2) MX2010005250A (es)
TN (1) TN2010000203A1 (es)
TW (2) TW200936143A (es)
WO (2) WO2009064414A1 (es)
ZA (1) ZA201002467B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
JP6129203B2 (ja) * 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
EP2800568A4 (en) * 2012-01-06 2015-06-10 Univ South Florida COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
SG11201406123TA (en) * 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6324409B2 (ja) * 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
JP2016509594A (ja) * 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
JP6346904B2 (ja) * 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
FI3604316T3 (fi) 2014-05-05 2024-02-29 Melinta Therapeutics Inc Boronaattisuolojen synteesi
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) * 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2686740C2 (ru) * 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EA201692301A1 (ru) * 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
KR20170062518A (ko) * 2014-10-01 2017-06-07 메르크 파텐트 게엠베하 보론산 유도체
CN107108660B (zh) * 2014-10-01 2020-09-15 默克专利股份公司 硼酸衍生物
ES2873000T3 (es) * 2014-10-01 2021-11-03 Merck Patent Gmbh Derivados del ácido borónico.
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN107207537B (zh) 2014-12-19 2019-05-31 莱姆派克斯制药公司 用于生产硼酸衍生物的设备和连续流方法
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR102512201B1 (ko) 2016-06-21 2023-03-20 오리온 옵탈몰로지 엘엘씨 지방족 프롤린아미드 유도체
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
ES3015371T3 (en) 2017-03-06 2025-05-05 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
WO2018218190A1 (en) * 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
TW201906616A (zh) * 2017-07-06 2019-02-16 日商大日本住友製藥股份有限公司 醯胺衍生物
WO2019009369A1 (ja) * 2017-07-06 2019-01-10 大日本住友製薬株式会社 イミン誘導体
EP3694864B1 (en) 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
JP7360132B2 (ja) * 2018-04-27 2023-10-12 住友ファーマ株式会社 オキソ置換化合物
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020112542A1 (en) * 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
CN110156820B (zh) * 2019-04-25 2021-06-25 四川大学 一类巯基酰胺硼酸类衍生物及其作为mbl和/或sbl抑制剂的用途
PT3986419T (pt) 2019-06-19 2025-07-31 Qpex Biopharma Inc Derivados de ácido borónico e suas utilizações terapêuticas
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
WO2022187362A1 (en) * 2021-03-02 2022-09-09 Case Western Reserve University Β-lactamase inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288253A1 (en) * 2002-09-09 2005-12-29 Trigen Limited Boronic acid salts
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
JP2007505950A (ja) * 2003-06-10 2007-03-15 フルクラム・ファーマシューティカルズ・インコーポレーテッド β−ラクタマーゼ阻害剤およびその使用方法
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors

Also Published As

Publication number Publication date
US20100317621A1 (en) 2010-12-16
AU2008321444A1 (en) 2009-05-22
MX2010005252A (es) 2011-04-11
JP2011503181A (ja) 2011-01-27
KR20100113485A (ko) 2010-10-21
IL205205A0 (en) 2010-12-30
EP2220096A1 (en) 2010-08-25
WO2009064414A1 (en) 2009-05-22
CA2705393A1 (en) 2009-05-22
BRPI0820532A2 (pt) 2012-07-10
AR069463A1 (es) 2010-01-27
MX2010005250A (es) 2010-11-05
MA31874B1 (fr) 2010-11-01
TW200936143A (en) 2009-09-01
AR069310A1 (es) 2010-01-13
KR20100109901A (ko) 2010-10-11
BRPI0820531A2 (pt) 2012-07-10
TN2010000203A1 (en) 2011-11-11
EP2220097A1 (en) 2010-08-25
CA2705389A1 (en) 2009-05-22
JP2011504468A (ja) 2011-02-10
GT201000143A (es) 2012-04-30
TW200930707A (en) 2009-07-16
ZA201002467B (en) 2011-02-23
AU2008321443A1 (en) 2009-05-22
ECSP10010246A (es) 2010-07-30
CN101861324A (zh) 2010-10-13
EA201000775A1 (ru) 2010-12-30
EA201000774A1 (ru) 2010-12-30
US20100286092A1 (en) 2010-11-11
CO6331427A2 (es) 2011-10-20
CN101983203A (zh) 2011-03-02
WO2009064413A1 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
ECSP10010246A (es) Inhibidores de beta-lactamasa
UY32626A (es) Inhibidores de beta-lactamasa
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CR9851A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
MX2019010602A (es) Inhibidores de cdk.
CR20110216A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
HN2007000267A (es) Compuestos de 4-metil piridopirimidinoma
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP099721A (es) Inhibidores de cinasa p70 s6
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CR20110135A (es) INHIBIDORES DE cMET
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
CR10148A (es) Derivados de las benzamidas y heteroarenos
CR20110562A (es) Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos
UY30796A1 (es) 3-h-pirazolopiridinas y sales de éstas, composiciones farmacéuticas que las comprenden, métodos para prepararlas, y sus usos
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY31001A1 (es) Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
DOP2009000215A (es) Administracion semanal de inhibidores de peptidasa de pipeptidilo
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)